Guardant Health, Inc. (GH) Fair Value 2026

GH · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.0 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-08-28, Guardant Health, Inc. (GH) trades at $161.50. QOC: 7.0/10. Value Trap Risk: 6/100 (SAFE). 0/13 models active.

Key Facts

Ticker
GH
Price
$161.50
Quality Score
7.0/10
Value Trap Risk
6/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give GH?

0 Intrinsic Value Models vs. Current Price ($161.50)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Guardant Health, Inc. (GH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Guardant Health, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About GH?

0 of 13 models are currently active for GH. See which stocks rank higher →

How Does GH Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, GH ranks #23 by Quality of Company score. CirclFi's QOC score of 7.0/10 evaluates 32 fundamental signals. A score of 7.0 indicates above-average quality.

Within the Diagnostics & Research space, Guardant Health, Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is GH a Value Trap?

CirclFi's Value Trap algorithm assigns GH a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Guardant Health, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Guardant Health, Inc. is rated at 7.0/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Guardant Health, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

ADPTAdaptive Biotechnologies CorporationQOC 7.2FLGTFulgent Genetics, Inc.QOC 7.0CDNACareDx, Inc.QOC 7.3CRLCharles River Laboratories International, Inc.QOC 6.9TWSTTwist Bioscience CorporationQOC 7.4PRPOPrecipio, Inc.QOC 6.7GRALGRAIL, Inc.QOC 6.2QGENQiagen N.V.QOC 3.2SHCSotera Health CompanyQOC 8.1IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: ADPT · FLGT · CDNA · CRL · TWST · PRPO · GRAL · QGEN · SHC · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to GH?

7 companies across all industries closest to GH’s Quality of Company score of 7.0/10.

ADTNADTRAN Holdings, Inc.QOC 7.0STRWStrawberry Fields REIT, Inc.QOC 7.0BWENBroadwind, Inc.QOC 7.0ONDSOndas Inc.QOC 7.0VFCV.F. CorporationQOC 7.0VIRCVirco Mfg. CorporationQOC 7.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ADTN · STRW · BWEN · ONDS · VFC · VIRC · NVDA

What Else Do Investors Ask About Guardant Health, Inc.’s Valuation?

What is Guardant Health, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Guardant Health, Inc. (GH). The Quality of Company score is 7.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GH overvalued or undervalued right now?

At $161.50, 0 of 0 active models suggest GH may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Guardant Health, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 7.0 mean for GH?

Guardant Health, Inc.'s QOC of 7.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on GH?

CirclFi analyzes GH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is GH a value trap in 2026?

Guardant Health, Inc.'s Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Guardant Health, Inc. (GH) a Quality of Company score of 7.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/GH/ · Methodology
Primary sources for this GH valuation
  • Financial statements: Guardant Health, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001576280) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GH as of ; valuations recomputed .